Compare WBI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBI | PHAT |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 942.6M |
| IPO Year | 2025 | 2019 |
| Metric | WBI | PHAT |
|---|---|---|
| Price | $22.80 | $14.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $27.25 | $17.60 |
| AVG Volume (30 Days) | 463.4K | ★ 838.1K |
| Earning Date | 11-12-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $733,296,000.00 | $147,190,000.00 |
| Revenue This Year | $21.11 | $218.59 |
| Revenue Next Year | $12.13 | $84.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $21.08 | $2.21 |
| 52 Week High | $27.12 | $16.27 |
| Indicator | WBI | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 53.42 |
| Support Level | N/A | $14.61 |
| Resistance Level | N/A | $16.27 |
| Average True Range (ATR) | 0.00 | 0.77 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 0.00 | 21.91 |
WaterBridge Infrastructure LLC is integrated, pure-play water infrastructure company with operations predominantly in the Delaware Basin, the prolific oil and natural gas basin in North America. It operates the largest produced water infrastructure network in the United States through which it provides water management solutions to oil and natural gas E&P companies under long-term contracts, which include gathering, transporting, recycling and handling produced water. It also operate two energy waste management facilities for the disposal of non-hazardous waste resulting from oil and gas E&P activities, branded under Desert Environmental. The transportation, treatment and handling of produced water is crucial to oil and natural gas production.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.